⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21640137 | 0.98 | GBA1 (0.33) | — | |
| SCHEMBL23361363 | 0.93 | GBA1 (0.37) | — | |
| SCHEMBL2387895 | 0.85 | — | — | |
| SCHEMBL20233801 | 0.83 | TSHR (0.40) | — | |
| SCHEMBL24764467 | 0.83 | CHRM1 (0.38) | — | |
| SCHEMBL24764219 | 0.83 | CHRM1 (0.38) | — | |
| Hydrochloric Acid SCHEMBL30043415 | 0.81 | CHRM1 (0.37) | — | |
| Hydrochloric Acid SCHEMBL30042301 | 0.81 | CHRM1 (0.37) | — | |
| SCHEMBL2747396 | 0.77 | SLC6A2 (0.34) | — | |
| SCHEMBL20233808 | 0.77 | MEN1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20220380376-A1 | Nitrogen Oxide-Donating PDE-5 and/or PDE-6 Inhibitor Compounds | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-12-01 | — | — | US | disclosed |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
| EP-4058457-A2 | NITROGEN OXIDE-DONATING PDE-5 AND/OR PDE-6 INHIBITOR COMPOUNDS | Ildong Pharmaceutical Co., Ltd. (KR) | 2022-09-21 | — | — | EP | disclosed |
| CN-115038704-A | Nitrogen oxide donating PDE-5 and/or PDE-6 inhibitor compounds | 日东制药股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| US-20220153746-A1 | NITROGEN OXIDE-DONATING PDE-5 AND/OR PDE-6 INHIBITOR COMPOUNDS, AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-05-19 | — | — | US | disclosed |
| US-20220153746-A1 | NITROGEN OXIDE-DONATING PDE-5 AND/OR PDE-6 INHIBITOR COMPOUNDS, AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-05-19 | — | — | US | disclosed |
| WO-2022096930-A2 | NITROGEN OXIDE-DONATING PDE-5 AND/OR PDE-6 INHIBITOR COMPOUNDS, AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022096930-A2 | NITROGEN OXIDE-DONATING PDE-5 AND/OR PDE-6 INHIBITOR COMPOUNDS, AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-05-12 | — | — | WO | disclosed |
| WO-2021094830-A2 | NITROGEN OXIDE-DONATING PDE-5 AND/OR PDE-6 INHIBITOR COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2021-05-20 | — | — | WO | disclosed |
| WO-2018102067-A2 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |